tp53 gene test for hematolymphoid malignancies and multiple myelomas | MedGenome

tp53 gene test for hematolymphoid malignancies and multiple myelomas

MedGenome and Fortis Memorial Research Institute cordially invite you to a webinar on

Role of TP53 Gene in Hematolymphoid Malignancies and Multiple Myeloma

Date & Time:
22nd May, 2020; 4pm - 5pm

Mutations of the TP53 gene and dysregulation of the TP53 pathway are important in the pathogenesis of many human cancers, including leukemias, lymphomas and myelomas. Tumor suppressor p53 protein (cellular tumor antigen p53), is “the guardian of the genome,” preserves genome stability under cellular stress, and is involved in various processes of development, differentiation, aging, and disease.

Dysfunction of p53 in human cancers can result from deletion, mutations, and dysregulation of TP53 gene expression and other p53 related activities. These mechanisms provide multiple ways to inactivate the functions of the TP53 pathway. This opens up a wide spectrum of applications of TP53 gene testing for hematolymphoid malignancies as well as Multiple Myeloma.

Speaker
Dr. Vidya Veldore

Principal Scientist, Oncology - MedGenome Labs Ltd

Moderator
Dr. Rahul Bhargava,

Director & HOD – Haematology, Haemato Oncology and BMT, Fortis Memorial Research Institute, Gurugram

Call in or send us your questions in advance and our experts will address them in this live session.

Can't attend live? You can still REGISTER! We will share the recording of the webinar with all registrants.

Future Medicine

Test Menu

Genetic Counselling

Microsites

Collaterals

Contact Us